regadenoson has been researched along with Tachycardia, Supraventricular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González Jimenez, A; Jimenez-Heffernan, A; Llamas Elvira, JM; Ramos-Font, C; Rashki, M | 1 |
| Ananthasubramaniam, K; Cabrera, R; Dhanalakota, S; Husain, Z; Jacobsen, G; Karthikeyan, AS; Palani, G; Pathmanathan, S | 1 |
2 other study(ies) available for regadenoson and Tachycardia, Supraventricular
| Article | Year |
|---|---|
Regadenoson long-lasting use induced tachyarrythmia.
Topics: Adenosine A2 Receptor Agonists; Aged; Drug Administration Schedule; Female; Humans; Purines; Pyrazoles; Tachycardia, Supraventricular | 2019 |
Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients.
Topics: Adenosine A2 Receptor Antagonists; Aged; Asthma; Atrioventricular Block; Bronchoconstriction; Chi-Square Distribution; Female; Heart Diseases; Hemodynamics; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Organophosphorus Compounds; Organotechnetium Compounds; Predictive Value of Tests; Pulmonary Disease, Chronic Obstructive; Purines; Pyrazoles; Radiopharmaceuticals; Retrospective Studies; Risk Assessment; Risk Factors; Tachycardia, Supraventricular; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2012 |